* Voyager remains on track to report top-line human
proof-of-concept data for VY-AADC01 in Q4 of 2016
The post BRIEF-Voyager Therapeutics says on track to report top-line human proof-of-concept data for VY-AADC01 in Q4 of 2016 appeared first on NASDAQ.